INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Innoviva, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$21.08+0.30 (+1.44%)
Close on Oct 19, 2026
- Market cap
- $1.55B
- P/E (TTM)
- 5.2
- Dividend yield
- –
Innoviva, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty Revenue | $56.33M | $55.17M | $54.90M | $59.90M | $63.88M | $57.81M | $62.52M | $57.06M | $63.74M | $58.42M | $66.17M | $53.56M | 47.1% | -11.8% |
| Net product sales | $51.77M | $41.37M | $59.06M | $47.29M | $35.49M | $30.28M | $28.94M | $27.82M | $21.65M | $19.08M | $19.68M | $13.70M | 43.3% | +45.9% |
| XACDURO | $22.38M | $18.07M | $32.07M | $23.81M | $10.73M | $7.78M | $6.71M | $9.78M | $2.34M | $2.24M | $1.40M | $600.00K | 18.7% | +108.6% |
| GIAPREZA | $22.30M | $20.23M | $19.55M | $18.46M | $17.33M | $18.27M | $16.07M | $13.78M | $13.11M | $12.08M | $13.09M | $8.00M | 18.6% | +28.7% |
| License and other revenue | $11.49M | $1.46M | $653.00K | $610.00K | $910.00K | $546.00K | $351.00K | $4.63M | $14.51M | $0 | – | – | 9.6% | +1162.2% |
| XERAVA [Member] | $6.74M | $2.63M | $7.29M | $4.91M | $7.09M | $4.22M | $6.16M | $4.26M | $6.20M | $4.77M | $5.22M | $5.10M | 5.6% | -5.0% |
| ZEVTERA [Member] | $351.00K | $438.00K | $158.00K | $113.00K | $339.00K | $0 | $0 | $0 | $0 | – | – | – | 0.3% | +3.5% |
| License revenue | – | – | – | – | – | – | – | $4.63M | $14.51M | $0 | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Innoviva's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.